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 Oligodeoxynucleotide conjugates 1-15 carrying anchoring groups such as amino, thiol, 
pyrrole, and carboxyl groups were prepared. A post-synthetic modification protocol was 
developed. In this method 2’-deoxy-O4-(p-nitrophenyl)uridine-3-phosphoramidite was 
prepared and incorporated in oligonucleotides. Following assembly of the sequence, the 
modified nucleoside was made to react with different amines carrying the anchoring 
groups. At the same time protecting groups were removed to yield the desired 
oligonucleotide conjugates. In a second approach, amino, thiol and carboxylic groups 
were introduced into the 3’-end of the oligonucleotides by preparing solid supports 
loaded with the appropriate amino acids. Oligonucleotide-gold conjugates were 
prepared and their binding properties were examined. 
 
Introduction.- Oligonucleotide carrying gold nanoparticles were first described in 
1996 [1, 2]. These conjugates have been shown to form networked arrays [1, 3, 4] and 
to form predetermined dimeric and trimeric assemblies [2, 5]. The special properties of 
gold nanoparticles linked to oligonucleotides has attracted large interest due to their 
potential use in gene analysis [6-11]. In addition, oligonucleotides have been linked to 
monodispersed CdSe/ZnS quantum dots [12, 13] and core-shell Ag/Au nanoparticles 
[14].  
The preparation of oligonucleotide-gold nanoparticle conjugates is usually 
performed by reaction of oligonucleotides carrying thiol or dithiane androsterone [8, 9] 
with either citrate- [1,3,7-11,14] or phosphine-[5,15] stabilized gold nanoparticles or 
nanogold carrying maleimido groups [2]. Dithiothreitol (DTT)-stabilized CdSe/ZnS 
quantum dots were also activated with carbonyl diimidazole to further react with 
oligonucleotides carrying amino groups [13]. Oligonucleotides carrying amino and thiol 
groups are extensively used for the preparation of conjugates that carry a large variety 
of functionalities including fluorochromes, biotin, intercalators, enzymes, and reactive 
groups [16] as well as for producing oligonucleotide microarrays [17]. 
Electrochemically-addressed DNA matrixes can also be produced by using 
oligonucleotides carrying pyrrole groups. These oligonucleotides can be anchored onto 
a conducting polymer film by electrooxidization of a mixture of pyrrole and pyrrole-
bearing oligonucleotides [18]. Finally, a description is given of the preparation of 
oligonucleotides carrying a carboxyl group. The specific reactivity of the carboxyl 
group was further used to prepare oligonucleotide-daunomycin conjugates [19].  
Anchoring groups such as amino-, and thiol-groups can easily be introduced  at the 
5’end of oligonucleotides using phosphoramidites derived from aminoalcohols and 
mercaptoalcohols [16]. The introduction of anchoring groups at the 3’end is not so 
simple. Special linker molecules are needed to introduce the desired group between the 
succinyl linker and the oligonucleotide. Aminodiols and dithio compounds are the most 
commonly used linkers for the preparation of oligonucleotides carrying amino and thiol 
groups at the 3’end. Very little data is available on the preparation of oligonucleotides 
carrying pyrrole or carboxylic groups at the 3’end [18, 19].  
This paper describes the use of post-synthetic modification protocols (or the 
convertible nucleoside approach [20]) to prepare oligonucleotide carrying amino, thiol, 
pyrrole and carboxylic groups at predetermined sites. This strategy involves a 2’-
deoxyuridine derivative that carries a good leaving group (O4-p-nitrophenyl, [21]) being 
incorporated at specific oligonucleotide sites and converted into a modified nucleobase, 
which carries the desired anchoring group by nucleophilic attack of the appropriate 
amine (Scheme 1) while the other protecting groups are also removed at the same time. 
In a second strategy trifunctional amino acids were added at the 3’end of the 
oligonucleotide through the use of special solid-supports [22]. After the protecting 
groups are removed, the amino acid side chain generates the desired amino, thiol or 
carboxyl groups. Oligonucleotide-gold nanoparticle conjugates were also prepared and 
a report is given of their binding properties.  
 
Results.- 1. Synthesis of oligonucleotides carrying anchoring groups by the post-
synthetic modification approach. A derivative of 2’-deoxyuridine (dU) was selected as 
a convertible nucleoside [20]. For this purpose, the O4-(p-nitrophenyl) derivative of dU 
was prepared, as is described elsewhere [21]. The O4-(p-nitrophenyl) dU derivative was 
incorporated on controlled pore glass (CPG) in accordance with standard protocols [23, 
24]. The support carrying the O4-(p-nitrophenyl)dU derivative was used to prepare two 
oligonucleotide sequences: A) 6mer: 5’ TAG CTUNp 3’ and B) 17mer: TAG CTT GAC 
GAT AGG TUNp 3’ being UNp= O4-(p-nitrophenyl) dU.  
Phosphoramidite derivatives protected with the tert-butylphenoxyacetyl group were 
used to incorporate the natural bases. These groups are more labile than standard groups 
and are removed by amines and at the same time that the O4-(p-nitrophenyl)–dU 
derivative is being modified. The use of these protective groups prevents cytosine 
modification, which has been described when amines other than ammonia are used to 
remove protective groups in DNA synthesis [20]. A similar strategy has been 
successfully used to prepare N2-substituted guanine derivatives [25]. 
Aliquots of the hexamer sequence A were treated with the following amines (1 M 
aqueous solution): I) cystamine (NH2-CH2-CH2-S-S-CH2CH2NH2), II) N-(2-
aminoethyl)pyrrole [26], III) 2,2’-[(ethane-1,2-diyl)bis(oxy)]bis(ethynamine) (NH2-
(CH2-CH2-O)2-CH2-CH2-NH2), IV) hexane-1,6-diamine, V) triglycine (NH2-
(CH2CONH)2-CH2-COOH) and a thiol VI) 6-mercaptohexanol. The treatment with 
amine I yielded the hexamer 1 carrying a thiol group protected with as disulfide. Amine 
II generated the hexamer 2 carrying a pyrrole group. Amines III and IV generated 
hexamers 3 and 4 carrying an amino group linked through a polar (III) or apolar (IV) 
linker. Amine V produced the hexamer 5 carrying a carboxyl group. The thiol VI was 
selected to check whether a thiol group could also be used to incorporate molecules into 
the hexamer sequence. After the treatment, the resulting solutions were dry 
concentrated and desalted on a Sephadex G-25 column. The oligonucleotide-containing 
fractions were pooled and purified by reversed-phase HPLC. Mass spectrometry 
showed that the desired oligonucleotides (1-5) were obtained in all cases except one 
(Table 1). Treatment of the support with 6-mercaptohexanol did not yield any 
detectable oligonucleotide. Our belief is that the lack of product was due to 6-
mercaptohexanol not being able to cleave the oligonucleotide-support bond. However, 
the strong yellow colour of the solution did indicate that p-nitrophenol was released. 
Following the thiol treatment, ammonia was then used to break the linkage between the 
oligonucleotide and the support. The two-step treatment was successful and the 
hexamer 6 was also obtained (Table 1). In addition to the desired oligonucleotide there 
were variable amounts (10-20%) of the hexamer resulting from hydrolysis of the p-
nitrophenyl group. In order to prevent the hydrolysed product from forming, water was 
replaced with dry acetonitrile to dissolve the amine IV (1 M solution). In this case only 
the desired hexamer was obtained and no hydrolysed product was detected by HPLC, 
enzyme digestion or mass spectrometry. 
Post-synthetic modification protocols were then applied to the 17mer sequence B to 
produce oligonucleotides carrying thiol, amino and pyrrole groups. In this case, 
sequence B was treated with three amines : I) cystamine (NH2-CH2-CH2-S-S-
CH2CH2NH2), II) N-(2-aminoethyl)pyrrole and III) 2,2’-(ethylenedioxy)-diethylamine 
(NH2-(CH2-CH2-O)2-CH2-CH2-NH2). The resulting oligonucleotides were purified by 
HPLC using standard trityl-on, trityl-off conditions. Treatment of sequence B with 
diamine I yielded oligonucleotide 7 in a 42% yield (Table 2). This yield is similar to 
that obtained by standard methods. In the case of the diamine III, the yield was lower 
(22%), and much lower with amine II. Oligonucleotides 7-9 were characterized by mass 
spectrometry and by analysis of the nucleoside composition after enzyme degradation.  
Finally, the amount of excess amine necessary for the deprotection-modification 
reactions was determined. The support with hexamer A (200 nmol) was treated with 
decreasing amounts of hexane-1,6-diamine in acetonitrile: 1ml of 1 M solution and 
0.1ml of 1 M, 0.1 M and 0.01 M solution (5000-5 molar amine/hexamer ratio). Good 
results were obtained with 5000-50 molar amine/hexamer ratio. At the 5 molar amine/ 
hexamer ratio the oligonucleotide was not released from the support. Subsequent 
treatment of the support with ammonia gave a mixture of three oligonucleotides in an 
equimolar ratio: the desired oligonucleotide (4), the hydrolysed product (hexamer with 
dU) and the product of the reaction of the convertible nucleoside with ammonia 
(hexamer with dC).  
 
2. Synthesis of oligonucleotides carrying anchoring groups using trifunctional amino 
acids. The use of trifunctional amino acids to introduce anchoring groups at the 3’end 
of oligonucleotides was also studied. A recent protocol described for the stepwise 
synthesis of oligonucleotide-peptide chimeras [22] was selected. First, a special support 
carrying the succinate derivative of 6-aminohexanol linked to amino-functionalized 
supports by a succinyl linkage was prepared (Scheme 2). Two amino-functionalized 
supports were used: controled-pore glass (CPG) and polystyrene-polyethyleneglycol 
(PEG-PS). The trifunctional amino acid was assembled on the 6-aminohexanol-
succinyl-support using Boc-chemistry. To protect side chains, the ε-amino group of 
lysine was protected with the fluorenylmethoxycarbonyl (Fmoc) group, and the 
carboxyl group of glutamic acid and the thiol group were protected with the 
fluorenylmetyl (Fm) group. Coupling reactions were performed using 
triphenylphosphine and 2,2’-dithio-bis-(5-nitropyridine) [23] when CPG was used as 
solid support and Benzotriazol-1-yloxy)trispyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) mediated coupling was applied with PEG-PS. After the 
incorporation of the appropriate amino acid, assembly of the oligonucleotide chain 
requires the presence of a hydroxyl group. The 4-hydroxypropionic linker carrying the 
dimethoxytrityl [(MeO)2Tr] group for protection of the hydroxyl group [27] was used. 
The progress of amino acid and linker incorporation on PEG-PS supports was 
monitored by ninhydrin test [28]. This test was unreliable on CPG supports and for this 
reason a capping step was introduced after each coupling reaction. Standard 
phosphoramidites were used for oligonucleotide assembly. For synthesis of the 
oligonucleotide part, the standard synthesis cycle was used in the case of a CPG support 
and a special synthesis cycle with increased coupling time using PEG-PS. Although it 
has previously been reported that phosphoramidite coupling reactions on peptide-PEG-
PS-supports are inefficient in acetonitrile due to poor swelling of the support, this 
problem was overcome by using dichloromethane to dissolve the phosphoramidites 
[22]. However, attachment of just one single amino acid to the PEG-PS support 
produced no change in the solvents on phosphoramidite coupling. 
 Hexanucleotide sequences 10 and 11 were assembled according to scheme 2 on 
CPG- and PEG-PS- supports carrying Fm-protected Glu (Table 3). Following assembly 
of the sequences, standard ammonia deprotection was performed. In both cases, HPLC 
analysis of the resulting products gave one main product with the expected mass (Table 
3). Supports carrying hexanucleotides 10 and 11 were alternatively treated first with a 
0.5 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) solution (to remove the Fmoc group), 
followed by ammonia to prevent glutamine formation. HPLC profiles of the products 
obtained with or without DBU treatment were identical indicating that glutamine 
formation did not happen in at a detectable level (<10%) under standard ammonia 
deprotection. Likewise, oligonucleotides 12 and 13 were also assembled on CPG 
supports using glutamic acid as the amino acid component. These oligonucleotides were 
obtained in similar yields and purity (tested by gel electrophoresis, data not shown) as 
unmodified oligonucleotides. The carboxyl group functionalized oligonucleotides 12 
and 13 are used for anchoring oligonucleotides to amino-modified gold electrodes 
(work in progress). 
 Attempts to synthesize the hexanucleotide sequence C6 on CPG support carrying 
Fmoc-protected Lys were not successful. This was possibly due, to the poor coupling 
efficiency of the linkers and amino acid. On the contrary, the tetranucleotide sequence 
14 was assembled without any problems on PEG-PS carrying Lys(Fmoc) and, 
following ammonia deprotection, gave a main product with the correct mass (Table 3).  
 Finally, the dodecanucleotide sequence 15 containing Fm-protected Cys resulted 
from analogous synthetic steps. In this case, ammonia deprotection was performed with 
a mixture of concentrated ammonia and 50 mM DTT to prevent disulfide formation. A 
single peak in HPLC was obtained showing the expected mass (Table 3) and no dimer 
formation was observed even after several days with the HPLC-purified product kept in 
a solution without DTT. 
 
3. Synthesis and properties of oligonucleotide-gold nanoparticle conjugates. First, 
phosphine-stabilized gold nanoparticles (1.4nm) carrying either a carboxyl group active 
ester (hydroxy-2,5-dioxopyrrolodine-3-sulfonic acid sodium salt, sulfo-NHS) or a 
maleimido group (NANOGOLD, Nanoprobes Inc., USA) were selected to form defined 
conjugates carrying one oligonucleotide per particle (NANOGOLD particles 
statistically carry one reactive molecule incorporated into the phosphine shelf). 
Conjugation of maleimido-NANOGOLD to cysteine-oligonucleotide 15 was performed 
in 10% aqueous isopropanol. 0.1 M carbonate buffer (pH 9.0) was used for the 
conjugation of sulfo-NHS-NANOGOLD to amino-oligonucleotide 9. Conjugates were 
analyzed and purified by 2% agarose gel electrophoresis (Figure 1) as described 
elsewhere [5, 15]. NANOGOLD is uncharged and for this reason remained near the 
wells whereas oligonucleotide-NANOGOLD conjugates are negatively-charged and 
move towards the anode. Conjugation efficiency was judged to be similar between 
cyteine-oligonucleotide 15 and the thiol-oligonucleotide 16 prepared with commercially 
available chemicals. These conjugates will be used for the self-assembly of well-
defined gold nanoparticle architectures in solution [2, 5, 11] (work in progress). 
 In addition, oligonucleotides carrying thiol groups (15-19, Tables 3, 4) were reacted 
with citrate-stabilized gold nanoparticles (13nm) to obtain gold nanoparticles with 
several oligonucleotide molecules per nanoparticle [7]. Melting experiments with 
duplexes formed by complementary oligonucleotides 16 and 17 were studied by 
UV/Visible absorption spectroscopy. Marked changes in the optical absorption spectra 
observed as a function of increasing temperatures, included a substantial increase in the 
absorption at 260 nm and a shift (40nm) in the maximum position of the surface 
plasmon absorption mode of the Au nanoparticles (Fig. 2a). Both these features are in 
good agreement with previous studies, which assign these spectral changes to the 
binding of the derivatised Au nanoparticles with their complements [7]. Fig. 2b shows 
the temperature dependent melting of duplexes formed by sequences 16 and 17 at 260 
nm with and without Au nanoparticles attached. When nanoparticles are present, 
melting transitions occur over a small temperature range and with a large absorbance 
change, producing sharp well defined melting transitions. In contrast, unmodified 
oligonucleotide duplexes melt over broad temperature ranges and produce 
comparatively small absorption changes.  
 Further studies were carried out to measure the effects of introducing a gap in the 
stability of a three component oligonucleotide system, (20-23). Two short 
oligonucleotides (18 and 19) attached to Au nanoparticles were hybridized to 
complementary oligonucleotides 20-23 with an increasing number of bases inserted into 
the target oligonucleotide sequence. As can be seen from Figure 3 the introduction of 
unpaired bases into the target oligonucleotide results in a systematic lowering of the 
melting temperature. Again, the absorbance changes that occur during the melting of 
the three component oliognucleotide-nanoparticle conjugates are of greater magnitude 
and occur over narrower temperature ranges than with unmodified oligonucleotides. 
Similar results were obtained when oligonucleotide 18 was replaced by cysteine-
oligonucleotide 15 (Figure 4). Melting temperatures obtained with cysteine-
oligonucleotide 15 were the same (within an error of 0.3 ºC) as melting temperatures 
obtained with oligonucleotide 18 prepared with commercially available compounds 
(Table 5).  
 
Discussion. Oligonucleotides carrying several anchoring groups were prepared. The 
results obtained showed that O4-(p-nitrophenyl)dU is a versatile compound for the 
preparation of modified oligonucleotides carrying a variety of additional functional 
groups including thiol, amino, pyrrole and carboxyl groups on the nucleobase. The O4-
(p-nitrophenyl)dU modified oligonucleotides allow the different linker molecules to be 
fixed at specific sites. This may be an advantage for finding the optimal characteristics 
of linker molecules without having to prepare a large number of derivatives. Moreover, 
side reactions may occur if aqueous conditions are used. Changes to anhydrous solvents 
may have a positive effect. Although the convertible nucleoside was located in this 
study at the 3’end, this methodology allows the convertible nucleoside to be assembled 
at any position on the oligonucleotide. O4-(2,4,6-trimethylphenyl)-2’-deoxyuridine was 
previously used for similar purposes [20], and the use of a p-nitrophenyl as a more 
active leaving group in combination with the more labile tert-butylphenoxyacetyl (Tac) 
group for amino protection is preferred because the deprotection-modification reaction 
can be performed in one single step. Moreover, the intense yellow colour of the 
resulting p-nitrophenolate ion allows the development of nucleophilic substitution to be 
monitored.  
The use of trifunctional amino acids to incorporate amino-, thiol- and carboxylic-
groups at the 3’end of oligonucleotides was also studied. The use of base-labile groups 
protecting groups for the side chain functions of amino acids was compatible with 
oligonucleotide synthesis. The α-amino groups of the amino acids were protected with 
the Boc-group but these groups were removed prior to the oligonucleotide being 
assembled. Two linkers were needed to connect the amino acid to the desired 
oligonucleotide and 4-hydroxybutanoic acid and 6-aminohexanol, inexpensive 
compounds, were applied as starting materials. CPG and PEG-PS supports in general 
gave good results and were compatible with oligonucleotide synthesis without any 
change to the solvent used on the phosphoramidite coupling reactions.  
Finally, the hybridisation properties of oligonucleotide gold nanoparticle conjugates 
were investigated and it was shown that the conjugates in general gave sharper and 
more defined melting transitions than unmodified oligonucleotides.  
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Experimental Part 
 
General. Phosphoramidites and ancillary reagents used during oligonucleotide synthesis 
were from Applied Biosystems (PE Biosystems Hispania S.A., Spain), Cruachem 
(Cruachem Ltd., Scotland) and Glen Research (Glen Research Inc., USA). Amino acid 
derivatives were from Bachem (Bachem AG, Switzerland) and Novabiochem 
(Calbiochem-Novabiochem AG, Switzerland). The rest of the chemicals were purchased 
from Aldrich, Sigma or Fluka (Sigma-Aldrich Química S.A., Spain). Long chain amino 
controlled pore glass (LCA-CPG) was purchased from CPG (CPG, Inc., New Jersey, 
USA). Amino-polyethyleneglycol-polystyrene (PEG-PS) was purchased from 
PerSeptive (PerSeptive Biosystems, now Applied Biosystems USA). Solvents were from 
S.D.S. (S.D.S., France). (MeO)2Tr-protected-2’-deoxy-O4-(p-nitrophenyl)-uridine was 
synthesized according to literature [21]. Gold nanoparticles (13 nm, citrate stabilized) 
were prepared as described elsewhere [7], and NANOGOLD (1.4 nm, phosphine 
stabilized) carrying maleimido and sulfo-NHS ester functionalities were purchased 
from Nanoprobes (Nanoprobes, Inc., USA). 
Instrumentation. UV spectra were recorded on a UV-2301PC and a 2401 Shimadzu 
spectrophotometers. Mass spectra (matrix-assisted laser desorption ionization time-of-
flight, MALDI-TOF) were provided by Eurogentec and Mass spectrometry service at 
the University of Barcelona.  
 
Preparation of solid-supports. Solid-support carrying 2’-deoxy-O4-(p-nitrophenyl)-
uridine was prepared by reacting the 3’-hemisuccinate derivative of 5’-(MeO)2Tr-2’-
deoxy-O4-(p-nitrophenyl)-uridine [24] with amino controlled pore glass (long chain 
amino-CPG) using triphenylphosphine and 2,2’-dithio-bis-(5-nitropyridine) [23] for 
condensation.   
Solid supports (CPG and PEG-PS) carrying amino acids were prepared by sequential 
addition of the following compounds: 1) N6-Boc-6-aminohexan-1-ol hemisuccinate 
prepared by reaction of commercially available N6-Boc-6-aminohexan-1-ol with 
succinic anhydride and DMAP as reported elsewhere [24], 2) either Boc-Glu(Fm)-OH, 
or Boc-Lys(Fmoc)-OH, or Boc-Cys(Fm)-OH and 3) O4-(MeO)2Tr-4-hydroxybutyric 
acid p-nitrophenyl ester [27]. The addition of Boc-amino acids on PEG-PS was 
performed in dimethylformamide (DMF) using 5-fold excess of the appropriate amino 
acid, 5-fold excess of PyBOP and 10-fold excess of diisopropylethylamine (DIEA) for 
1 h at room temperature. The removal of the Boc-protecting group was performed using 
40% trifluoroacetic acid in dichloromethane. A neutralization step with 5% DIEA in 
dichloromethane and several washing steps were introduced between removal of the 
Boc-group and coupling. The coupling of the p-nitrophenyl ester of (MeO)2Tr-protected 
4-hydroxybutyric acid was performed in the presence of 1 equivalent of N-
hydroxybenzotriazole (HOBt) using 5-fold excess. A negative ninhydrine test was 
obtained after several hours at room temperature. As a precaution acetylation of 
unreacted amino groups was performed by a 10-min treatment of the support with a 
mixture of acetic anhydride / DIEA/ DMF (1:1.7: 15.3 ml). The addition of Boc-amino 
acids to CPG supports was performed using triphenylphosphine and 2,2’-dithio-bis-(5-
nitropyridine) as coupling activating agents [23]. The coupling of the p-nitrophenyl 
ester of (MeO)2Tr-protected 4-hydroxybutyric acid was performed as described for 
PEG-PS supports. 
Oligonucleotide Synthesis. Oligonucleotide sequences were synthesized on an Applied 
Biosystems DNA synthesizer model 392 (Applied Biosystems, USA). 5’-(MeO)2-Tr-, 
(tert-butyl)phenoxyacetyl-protected-3’-(2-cyanoethyl-N,N-diisopropyl- 
phosphoramidites) were used for the synthesis of oligonucleotides carrying the 2’-
deoxy-O4-(p-nitrophenyl)-uridine moiety. The rest of the sequences were prepared 
using standard (Bz- or ibu-protected) 3’-phosphoramidites. Standard 1-μmol-scale 
synthesis cycles were used. Supports were prepared as described below. Coupling 
efficiencies were higher than 98%. 
 In addition to compounds 1-15, oligonucleotides carrying thiol groups at 5’end (16, 
17, 19) and the 3’end (18) were prepared using the phosphoramidite of (MeO)2-Tr-
protected 6-hydroxyhexyl disulfide and the CPG support functionalized with (MeO)2-
Tr-protected 3-hydroxypropyl disulfide (Glen Research, USA).  
Deprotection of oligonucleotides. Oligonucleotide supports carrying 2’-deoxy-O4-(p-
nitrophenyl)-uridine were treated with 1ml (or less) of 1 M aqueous solutions of the 
appropriate amine (Tables 1 and 2) at 55 ºC overnight and the solution was filtered and 
concentrated to dryness. The solution of N-(2-aminoethyl)pyrrole contained 10% of 
dioxane. Cystamine was obtained from commercial sources in a hydrochloride form. 
One equivalent of triethylamine was added to the cystamine solution to neutralize the 
hydrochloride. Two different deprotection protocols were used for oligonucleotide 
supports carrying lysine and glutamic acid at the 3’end. In the first protocol supports 
were treated directly with 1ml of ammonia (overnight, 55ºC). In the second protocol 
supports were treated with 1ml of 0.5 M DBU solution in acetonitrile for 30 min at 
room temperature. The support was washed in acetonitrile, 1% triethylamine in 
acetonitrile and acetonitrile and dried. The resulting support was then treated with 1ml 
of concentrated ammonia (overnight, 55ºC). Oligonucleotide supports carrying either 
cysteine at the 3’end or oligonucleotides carrying the 6-mercaptohexyl group at the 
5’end were treated overnight with 1ml of 50 mM dithio-DL-threitol (DTT) in 
concentrated ammonia at 55ºC.  
Purification of oligonucleotides. The resulting products were dissolved in water and the 
solution was desalted on a Sephadex G-25 column (NAP-10, Pharmacia, Sweden). The 
oligonucleotide-containing fractions were analyzed and purified by HPLC, as follows: 
Column : PRP-1, 10 μm (Hamilton, USA) (305 x 7mm), flow rate 3ml / min. A 20min 
linear gradient from 15 to 55% acetonitrile over 100 mM aqueous triethylammonium 
acetate was used for the oligonucleotide carrying the (MeO)2-Tr group. After removal 
of the (MeO)2-Tr group with 80% acetic acid (30min) the resulting oligonucleotides 
were purified on the same column using a 20min linear gradient from 5 to 25% 
acetonitrile over 100 mM aqueous triethylammonium acetate. Purified oligonucleotides 
were analyzed by mass spectrometry (MALDI-TOF). The results are shown in Tables 
1-3. 
 
Enzymatic analysis of oligonucleotides. Oligonucleotides prepared by postsynthetic 
modification (0.5-1 OD units) were incubated in 50 mM tris HCl pH 8.0 and 10 mM 
MgCl2 with snake venom phosphodiesterase (Pharmacia Biotech, Sweden) and 
bacterial alkaline phosphatase (Pharmacia Biotech, Sweden) in a total volume of 
0.03ml at 37ºC overnight. The resulting mixture was diluted and analyzed by HPLC. 
Column : C-18 Nucleosil, 5 μm (250 x 4 mm), flow rate 1ml/min. A 20 min linear 
gradient from 5 to 22% acetonitrile over 20 mM aqueous triethylammonium acetate was 
used, followed by 5 min of isocratic conditions at 22% acetonitrile . Retention times 
observed under these conditions were dC 3.6 min, dU (hydrolysis product) 4.3 min, dG 
6.1 min, T 7.0 min, dA 9.7 min. Modified dC derivatives: N4-(2-pyrrolethyl)-dC 15.8 
min, N4-{2-[2-(2-aminoethyl)oxyethyl]oxyethyl}-dC 11.4 min, N4-(2-(2’-
aminoethyl)dithioethyl)-dC 8.1 min, N4-(6-aminohexyl)-dC 12.6 min, S4-(6-
hydroxyhexyl)-4-thio-dU 24.0 min (UV max at 330 nm).  
 
Preparation of Au nanoparticles and Oligonucleotides prior to conjugation. Au 
nanoparticles were prepared by the citrate reduction of HAuCl4 as described elsewhere 
[7]. Nanoparticles were analysed by UV-Vis absorption spectroscopy (Shimadzu 2401 
spectrophotometer) and TEM (JEOL JEM 1200-EX). Oligonucleotides were desalted 
prior use on a NAP-10 (Pharmacia) column using a 10 mM sodium phosphate buffer 
(pH 7) as solvent. The resulting fractions were analysed by UV-Vis.   
 
Preparation of oligonucleotide-gold conjugates. Conjugation of maleimido-
NANOGOLD to thiol-oligonucleotides was performed by following the 
recommendations of the suppliers’. Aliquotes of liophylized maleimido-NANOGOLD 
(6 nmols) were mixed with thiol-oligonucleotides (6 nmols) dissolved in 10% aqueous 
isopropanol. The resulting mixtures were kept overnight at room temperature and the 
resulting solutions were stored in the refrigerator until further use. A similar protocol 
was used for the conjugation of amino-oligonucleotides to sulfo-NHS-NANOGOLD. In 
this case 0.1 M carbonate buffer (pH 9.0) was used as a reaction buffer. Conjugates 
were purified by 2% agarose gel electrophoresis (0.5xTBE) as described elsewhere [5, 
15].  
 Furthermore, oligonucleotide carrying thiol groups were also conjugated to citrate-
stabilized gold nanoparticles. The desalted thiolated oligonucleotide was removed from 
the freezer and allowed to thaw. The optical absorbance of both the oligonucleotide and 
nanoparticle samples was measured. The nanoparticles and oligonucleotide were mixed 
in appropriate amounts and the entire solution was brought to 10 mM sodium phosphate 
buffer (pH 7). After one day, the solution was brought to 0.1 M NaCl concentration and 
allowed to stand at room temperature for another 40 hours. After this time, the solution 
was centrifuged at 13,200 rpm for 30 min. Supernatant was removed and the reddish 
solid at the bottom was dispersed in 0.1 M NaCl, 10 mM sodium phosphate buffer (pH 
7) solution (the volume added was similar to that removed). This procedure was 
repeated by applying 0.3 M NaCl and 10 mM phosphate buffer (pH 7). The solution was 
analysed by UV-Vis spectroscopy and the absorbance at 260nm was recorded for future 
use. The solution was stored at room temperature. 
 
Melting experiments. Melting experiments were carried out using equimolar amounts of 
each oligonucleotide-gold nanoparticle conjugate in 0.3 M NaCl, 10 mM sodium 
phosphate buffer, pH 7. The solution was heated to 90º for 5 min and then allowed to 
cool to room temperature for 48 hours. The solution was transferred to a stoppered 1-
cm path-length cuvette and UV-Vis spectra were recorded at 5º intervals while the 
sample was heated from 20-90º at 5ºC/5 min. Heating of the UV cuvette was performed 
with a Grant W6-KD precision thermostatic circulator attached to a Shimadzu constant 
temperature cell holder. Calibration spectra were recorded to determine the heat transfer 
efficiency to the cuvette. The data were collected as wavelength versus absorbance 
spectra and a plot of temperature versus absorbance at 260nm was drawn.  The melting 
temperature of the systems was determined from these graphs. 
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Table 1: Mass spectrometry analysis of the oligonucleotide resulting from the treatment of 
hexanucleotide-support 5’TAGCTUNp-CPG 3’ with amines or thiols. 
 
Compound Amine/thiol used Yield M (found) Calc. 
1 I) (NH2-CH2-CH2-S)2 35% 1903 1903 
2 II) NH2-CH2-CH2-pyrrole 10% 1861 1862 
3 III) NH2-(CH2-CH2-O)2-CH2-CH2-NH2 30% 1900 1899 
4 IV) NH2-(CH2)6-NH2 25% 1868 1867 
5 V) NH2-(CH2CONH)2-CH2-COOH 25% 1941 1940 
6 VI) HS-(CH2)6-OHa 15% 1885 1885 
aAmmonia was needed to release the hexamer from the support after it was treated with the 
thiol. 
 Table 2: Yield and mass spectra of oligonucleotides resulting from the treatment of 17mer-
support TAGCTTGACGATAGGTUNp-CPG 3’ with different amines. 
 
Compound Amine/thiol used Yield M (found) Calc. 
7 I) (NH2-CH2-CH2-S)2 42% 5361 5360 
8 II) NH2-CH2-CH2-pyrrole 7% 5318 5318 
9 III) NH2-(CH2-CH2-O)2-CH2-CH2-NH2 22% 5375 5376 
 
 Table 3. Oligonucleotide sequences carrying trifunctional amino acids at the 3’end 
prepared in the present study. 
 
Compound Sequence 5’->3’ Solid supporta Yield M (found) Calc.
10 CCCCCC Glu(Fm)CPG 22% 2066 2067
11 TTTTTT Glu(Fm)PEG-PS 20% 2154 2157
12 GAGCTACTGAGTTACTGAGC Glu(Fm)CPG 43% n.d.  
13 GCTCAGTAACTCAGTAGCTC Glu(Fm)CPG 40% n.d.  
14 CCCC Lys(Fmoc)PEG-PS 35% 1486 1488
15 TCTCAACTCGTA Cys(Fm)CPG 40% 3947 3948
aAbbreviations: CPG: controlled pore glass, PEG-PS: polyethyleneglycol-polystyrene, Fm: 
fluorenylmethyl, Fmoc: fluorenylmethoxycarbonyl. n.d. not determined. 
 
 Table 4: Oligonucleotide sequences prepared using standard methods. 
Compound Sequence 5’->3’ 
16 Thiol-hexyl-CGAGTCATTGAGTCATCGAG 
17 Thiol-hexyl-CTCGATGACTCAATGACTCG 
18 TCTCAACTCGTA-propyl-thiol 
19 Thiol-hexyl-CGCATTCAGGAT 
20 TACGAGTTGAGAATCCTGAATGCG 
21 TACGAGTTGAGACATCCTGAATGCG 
22 TACGAGTTGAGACCATCCTGAATGCG 
23 TACGAGTTGAGACCCATCCTGAATGCG 
 
 Table 5: Comparison of melting temperatures obtained with a DNA assembly made of three 
components, a target oligonucleotide sequence (20-23) with an increasing number of inserted 
bases and two short oligonucleotide-Au nanoparticle conjugates. In the first column, 
thiolated oligonucleotides 18 and 19 were used while cysteine-oligonucleotide 15 and 
thiolated-oligonucleotide 19 were used in the next column. Conditions 0.3 M NaCl and 10 
mM sodium phosphate pH7. 
  
Template Number of insertions Oligonucleotide 18
Tm(ºC) 
Oligonucleotide 15
Tm(ºC) 
20 0 51.8 51.2 
21 1 47.6 47.5 
22 2 47.4 47.0 
23 3 46.4 46.7 
 
 LEGENDS 
Scheme 1: Synthesis of oligonucleotides carrying anchoring groups by postsynthetic 
modification protocol. 
 
Scheme 2: Synthesis of oligonucleotides carrying trifunctional amino acids at the 3’end. Lys 
(Fmoc), R= (CH2)4-NH-Fmoc. Cys (Fm), R= CH2-S-Fm. Glu(Fm), R= (CH2)2-COO-Fm  
 
Figure 1: 2% Agarose gel (0.5x Tris-Borate-EDTA (TBE)) of oligonucleotide-gold nanoparticle 
conjugates. The gel was run at 80 volts for 20 min. Lane 1: Maleimido-NANOGOLD. Lane 2: 
Reaction of cysteine-oligonucleotide 15 with maleimido-NANOGOLD. Lane 3: Reaction of 
thiol-oligonucleotide 16 with maleimido-NANOGOLD. Lane 4: Reaction of amino-
oligonucleotide 9 with sulfo-NHS-NANOGOLD. Lane 5: Bromophenolblue and xylenecyanol 
dyes. 
 
Figure 2: Hybridization and melting of oligonucleotide-gold nanoparticle conjugates. A) UV-
spectra of duplex formed with oligonucleotide-gold nanoparticle conjugates 16 and 17. B) 
Melting profiles at 260nm of duplex formed by sequences 16 and 17 with and without gold 
nanoparticles.  
 
Figure 3: Melting profiles at 260nm of thiol-modified oligonucleotide- Au nanoparticle 
conjugates. A) Target oligonucleotide sequences (20-23) with an increasing number of inserted 
bases were mixed with unmodified oligonucleotide sequences 18 and 19. B) Target 
oligonucleotide sequences (20-23) were mixed with thiolated oligonucleotide sequences 18 and 
19 attached to Au nanoparticles (0.3 M NaCl and 10 mM sodium phosphate pH 7). 
 
Figure 4: Melting profiles at 260nm of cysteine-modified oligonucleotide- Au nanoparticle 
conjugate. Target oligonucleotide sequences (20-23) with an increasing number of inserted 
bases were mixed with oligonucleotides 15 and 19 attached to Au nanoparticles (0.3 M NaCl 
and 10 mM sodium phosphate pH 7). 
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